Citations

Clear

4847 citation(s) found for "Yu, Eric".

Biomarker clustering in autosomal dominant Alzheimer's disease
Luckett, Patrick H. , Chen, Charlie, Gordon, Brian A. , Wisch, Julie K. , Berman, Sarah , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Cash, David M. , Fulham, Michael , Jack, Clifford R. , Vöglein, Jonathan , Klunk, William E. , Wang, Qing , Marcus, Daniel C. , Koudelis, Deborah, Cash, Lisa, Hornbeck, Russ C. , Perrin, Richard J. , Hassenstab, Jason , Morris, John C. , Bateman, Randall J. , (DIAN), for the Dominantly Inherited Alzheimer Network, Cruchaga, Carlos , Jack, Clifford R , Gordon, Brian A , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Cash, David M , Wisch, Julie K , Berman, Sarah , Noble, James M , Jucker, Mathias , Schofield, Peter R. , Brickman, Adam M. , Brooks, William S. , Ghetti, Bernardino , Koeppe, Robert A. , Su, Yi , Weiner, Michael W. , Marcus, Daniel, Joseph‐Mathurin, Nelly , Xiong, Chengjie , Karch, Celeste M. , McDade, Eric , Benzinger, Tammie L.S. , Ances, Beau M. , (DIAN), for the Dominantly Inherited Alzheimer Network

Mayo Clinic

Alzheimer's & Dementia | April 1, 2022 | Volume: 19 | Issue: 1 | Pages: 274-284

10.1002/alz.12661 | PMID 35362200 Get It

AbstractINTRODUCTIONAs the number of biomarkers used to study Alzheimer's disease (AD) continues to increase, it is important to understand the utility of any given biomarker, as well as what additional information a biomarker provides when compared to others.METHODSWe used hierarchical clustering to group 19 cross‐sectional biomarkers in autosomal dominant AD. Feature selection identified biomarkers that were the strongest predictors of mutation status and estimated years from symptom onset (EYO). Biomarkers identified included clinical assessments, neuroimaging, cerebrospinal fluid amyloid, and tau, and emerging biomarkers of neuronal integrity and inflammation.RESULTSThree primary clusters were identified: neurodegeneration, amyloid/tau, and emerging biomarkers. Feature selection identified amyloid and tau measures as the primary predictors of mutation status and EYO. Emerging biomarkers of neuronal integrity and inflammation were relatively weak predictors.DISCUSSIONThese results provide novel insight into our understanding of the relationships among biomarkers and the staging of biomarkers based on disease progression.
Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX
Shropshire, William C. , Dinh, An Q , Earley, Michelle, Komarow, Lauren , Panesso, Diana , Rydell, Kirsten, Gómez-Villegas, Sara I, Miao, Hongyu , Hill, Carol , Chen, Liang , Patel, Robin , Abbo, Lilian M. , Cober, Eric , Revolinski, Sara , Luterbach, Courtney , Chambers, Henry F. , Fowler, Vance G. , Shelburne, Samuel A. , Kreiswirth, Barry N. , Hanson, Blake , Arias, César A. , Revolinski, Sara , Bonomo, Robert A , Shelburne, Samuel A , Kreiswirth, Barry N , van Duin, David , Hanson, Blake M , Chen, Liang , Patel, Robin , Abbo, Lilian M , Fries, Bettina C. , Fowler, Vance G. , Bonomo, Robert A. , Arias, César A.

Mayo Clinic

mBio | March 31, 2022 | Volume: 13 | Issue: 2 | Pages: No page available

10.1128/mbio.00497-22 | PMID 35357213 Get It

The prevalence of carbapenem-resistant Klebsiella pneumoniae (CR Kp ) infections in nosocomial settings remains a public health challenge. High-risk clones such as clonal group 258 (CG258) are particularly concerning due to their association with bla KPC carriage, which can severely complicate antimicrobial treatments.
Differences in postoperative quality of life in young, early elderly, and late elderly patients undergoing surgical treatment for degenerative cervical myelopathy
Croci, Davide M., Sherrod, Brandon, Alvi, Mohammed Ali, Mummaneni, Praveen V., Chan, Andrew K., Bydon, Mohamad, Glassman, Steven D., Foley, Kevin T., Potts, Eric A., Shaffrey, Mark E., Coric, Domagoj, Knightly, John J., Park, Paul, Wang, Michael Y., Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L., Than, Khoi D., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S., Bisson, Erica F., Park, Paul , Alvi, Mohammed Ali , Alvi, Mohammed Ali , Croci, Davide M., Sherrod, Brandon, Alvi, Mohammed Ali, Mummaneni, Praveen V., Chan, Andrew K., Bydon, Mohamad, Glassman, Steven D., Foley, Kevin T., Potts, Eric A., Shaffrey, Mark E., Coric, Domagoj, Knightly, John J., Park, Paul, Wang, Michael Y., Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L., Than, Khoi D., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S., Bisson, Erica F.

Mayo Clinic

Journal of Neurosurgery: Spine | March 25, 2022 | Volume: 37 | Issue: 3 | Pages: 339-349

10.3171/2022.1.spine211157 | PMID 35276658 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) is a common progressive spine disorder affecting predominantly middle-aged and elderly populations. With increasing life expectancy, the incidence of CSM is expected to rise further. The outcomes of elderly patients undergoing CSM surgery and especially their quality of life (QOL) postoperatively remain undetermined. This study retrospectively reviewed patients to identify baseline differences and validated postoperative patient-reported outcome (PRO) measures in elderly patients undergoing CSM surgery. METHODS The multi-institutional, neurosurgery-specific NeuroPoint Quality Outcomes Database was queried to identify CSM patients treated surgically at the 14 highest-volume sites from January 2016 to December 2018. Patients were divided into three groups: young (< 65 years), early elderly (65–74 years), and late elderly (≥ 75 years). Demographic and PRO measures (Neck Disability Index [NDI] score, modified Japanese Orthopaedic Association [mJOA] score, EQ-5D score, EQ-5D visual analog scale [VAS] score, arm pain VAS, and neck pain VAS) were compared among the groups at baseline and 3 and 12 months postoperatively. RESULTS A total of 1151 patients were identified: 691 patients (60%) in the young, 331 patients (28.7%) in the early elderly, and 129 patients (11.2%) in the late elderly groups. At baseline, younger patients presented with worse NDI scores (p < 0.001) and lower EQ-5D VAS (p = 0.004) and EQ-5D (p < 0.001) scores compared with early and late elderly patients. No differences among age groups were found in the mJOA score. An improvement of all QOL scores was noted in all age groups. On unadjusted analysis at 3 months, younger patients had greater improvement in arm pain VAS, NDI, and EQ-5D VAS compared with early and late elderly patients. At 12 months, the same changes were seen, but on adjusted analysis, there were no differences in PROs between the age groups. CONCLUSIONS The authors’ results indicate that elderly patients undergoing CSM surgery achieved QOL outcomes that were equivalent to those of younger patients at the 12-month follow-up.
Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
Iovleva, Alina , Mustapha, Mustapha M. , Griffith, M. Patrick , Komarow, Lauren , Luterbach, Courtney , Evans, Daniel R. , Cober, Eric , Richter, Sandra S. , Rydell, Kirsten, Arias, César A. , Jacob, Jesse T. , Salata, Robert A. , Satlin, Michael J. , Wong, Darren , Tyne, Daria Van , Doi, Yohei , Bonomo, Robert A , van Duin, David , Cooper, Vaughn S , Van Tyne, Daria , Doi, Yohei , Jacob, Jesse T , Griffith, Marissa P., Arias, César A. , Bonomo, Robert A.

Mayo Clinic

mBio | March 21, 2022 | Volume: 13 | Issue: 2 | Pages: No page available

10.1128/mbio.02759-21 | PMID 35311529 Get It

Carbapenem-resistant Acinetobacter baumannii (CR Ab ) constitutes a major threat to public health. To elucidate the molecular and clinical epidemiology of CR Ab in the United States, clinical CR Ab isolates were collected along with data on patient characteristics and outcomes, and bacterial isolates underwent whole-genome sequencing and antibiotic susceptibility phenotyping.
Antihypertensive Pharmacogenetics: The C825T Polymorphism of G-Protein β 3 Subunit ( GNB3 ) Is Associated with Greater Blood Pressure (BP) Response to Diuretic Therapy in Essential Hypertens
Schwartz, Gary L. , Chapman, Arlene B. , Boerwinkle, Eric , Turner, Stephen T. , Chapman, Arlene B.

Mayo Clinic

Hypertension | March 20, 2022 | Volume: 36 | Issue: suppl_1 | Pages: 684-684

10.1161/hyp.36.suppl_1.684-c Get It

37 Knowledge of genetic factors that influence pharmacodynamics of responses to antihypertensive drugs may provide insights into molecular mechanisms contributing to elevation of BP and response to treatment. The T-allele of the C825T polymorphism of the gene coding for the G-protein β 3 subunit ( GNB3 ) has been associated with increased Na + -H + exchange and low plasma renin in individuals with EHT. Moreover, diminished counterregulatory activity of the renin-angiotensin system has been associated with greater BP declines in response to negative sodium balance induced by diuretic therapy. To assess the possible influence of GNB3 genotype on BP response to diuretic therapy, we measured the C825T polymorphism in community-based samples of 204 blacks (139 women, 65 men) and 192 whites (77 women, 115 men) with EHT (mean age=48±7 years) who underwent monotherapy with hydrochlorothiazide (HCTZ) for 4 weeks. In univariate analyses, the TT genotype was significantly associated with lower plasma renin activity ( p <0.001) and higher plasma aldosterone concentration ( p <0.019). In addition, mean declines in systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 6±2 mmHg ( p <0.001) and 5±1 mmHg ( p <0.001) greater, respectively, in TT than in CC homozygotes. Responses in heterozygotes were intermediate between homozygote groups. Other univariate predictors of greater declines in both SBP and DBP were higher pretreatment BP ( p <0.001), black race ( p <0.001), female gender ( p <0.005), older age ( p ≤0.064), lower waist/hip ratio (p≤0.087), and lower plasma renin activity ( p <0.001). Even after considering effects of these other predictors, the TT genotype remained associated with greater declines in SBP ( p <0.058) and DBP ( p <0.001). Thus, the C825T polymorphism of GNB3 may help identify individuals with EHT who are more responsive to diuretic therapy and may have Na + -dependent BP elevation.
Abstract 283: Association of Body Mass Index with Outcomes in Patients with Atrial Fibrillation: Results From the ORBIT-AF Registry
Shrader, Peter, Thomas, Laine , Kowey, Peter R. , Sun, Shining, Burton, Paul , Piccini, Jonathan P. , Pandey, Ambarish , Gersh, Bernard J. , McGuire, Darren K. , Mahaffey, Kenneth W. , Hylek, Elaine M. , Peterson, Eric D. , Fonarow, Gregg C.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.283 Get It

Introduction: Higher body mass index (BMI) is an independent risk factor for incident atrial fibrillation (AF). However, its impact on management strategies and clinical outcomes among patients with prevalent AF is unclear. Methods: The study cohort included patients with AF enrolled in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry from June 2010 through August 2011. Participants with BMI > 18.5 kg/m2 were stratified into normal (18.5 - 25 kg/m2), overweight (25 - 30 kg/m2), Class I obese (30 - 35 kg/m2), Class II obese (35 - 40 kg/m2), and Class III obese (>40 kg/m2) categories. Unadjusted and adjusted Cox frailty models were constructed to assess the categorical and continuous association of BMI with AF progression, mortality, and incidence of thromboembolic events. Results: We evaluated 9,606 patients with AF (mean age: 74 + 11 years; 42% women) from 174 US ORBIT participating practices. Patients in the higher BMI categories were younger and had a higher prevalence of comorbidities such as diabetes, hypertension, and obstructive sleep apnea. AF symptom burden was greatest among patients in extreme BMI categories. Proportional use of anticoagulation, antiarrhythmic drugs, and invasive rhythm control strategies was significantly greater among patients in higher BMI categories. Rates for mortality and stroke/non-CNS embolism decreased in a near linear fashion across successively higher BMI categories (P<0.001; Table). After multivariable adjustment, higher BMI categories were associated with lower risk for mortality (p = 0.0002), with the lowest risk observed among overweight patients [Hazard Ratio (HR) (95% CI): 0.65 (0.54 - 0.79) ref. group: normal weight]. For every 5-kg/m2 increase in BMI, the odds of risk-adjusted mortality were 6% lower [HR (95% CI): 0.94 (0.89 - 0.98)]. In contrast, the association between BMI and risk for stroke/non-CNS embolism was significant on unadjusted analysis (P <0.001) but attenuated after adjustment for risk factors (P = 0.78; Table). No significant association was observed between BMI and AF progression rates in either unadjusted (P = 0.35) or adjusted analyses (P = 0.17). Conclusion: Among patients with AF, higher BMI was associated with a greater use of anticoagulation, rhythm control strategies, and lower mortality risk.
Abstract 332: Association of Body Mass Index with Health Status Outcomes in Patients Undergoing Percutaneous Coronary Intervention
Sharma, Praneet, Kureshi, Faraz , Buchanan, Donna M., Jayaram, Natalie , Grodzinsky, Anna , Salisbury, Adam C. , Fendler, Timothy J. , Tang, Fengming, Ting, Henry H. , Merrill, Eric Dean , Spertus, John A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.332 Get It

Background: An obesity paradox, with better long-term survival in obese patients undergoing percutaneous coronary intervention (PCI), has been well described. The association between obesity and health status outcomes after PCI is unknown. Methods: We prospectively enrolled 3,281 PCI patients in a 10-center observational cohort study and categorized their body mass index (BMI) into normal (18.5 to <25), overweight (25 to <30), obese (30 to <35) and morbidly obese (≥ 35).Generalized linear models were used to describe the association between BMI and health status measures at 6 & 12 months, after adjusting for baseline characteristics and health status scores. Health status outcomes included; Seattle Angina Questionnaire [SAQ] Angina Frequency (AF), and Quality of Life (QL) scores, as well as the EQ-5D visual analogue scale (EQ-5D VAS). Interaction with time was not significant, so an estimate of the average benefit over time was generated. Results: The distribution of patients’ BMI revealed that 17% were normal, 35% overweight, 28% obese and 20% morbidly obese. Compared with normal weight patients, morbidly obese individuals were younger (mean 60.8 yr vs. 67.9 yr) and had a higher prevalence of diabetes, hypertension and heart failure. They underwent radial artery access (12.0% vs. 7.0%) and drug eluting stent implantation (80.4% vs. 76.0%) more frequently. Unadjusted changes in scores were lower (worse) among morbidly obese as compared with normal weight patients for SAQ AF (mean difference [MD] -1.52; 95% Confidence Interval [CI] -3.05, -0.02), SAQ QL (MD -2.51; CI -4.48, -0.54), and EQ-5D VAS (MD -5.74;CI -7.52, -3.96). After adjustment, these differences were no longer significantly different for SAQ AF and SAQ QL (figure), although EQ-5D VAS scores remained lower among obese and morbidly obese patients. Conclusion: The overall health status was mildly worse among obese and morbidly obese individuals after PCI, but the benefits of PCI on patients’ disease-specific health status were similar across weight categories. This suggests that PCI is equally effective in improving angina and disease-specific quality of life, independent of patients’ weight.
Abstract 141: Outcomes Associated with Temporarily Interrupting Anticoagulation in Outpatients with Atrial Fibrillation: Results from ORBIT-AF
Kim, Sunghee , Thomas, Laine , Kowey, Peter R. , Piccini, Jonathan P. , Ansell, Jack , Steinberg, Benjamin A. , Sherwood, Matthew W. , Gersh, Bernard J. , Fonarow, Gregg C. , Mahaffey, Kenneth W. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.141 Get It

Background: Interruption of OAC is often required for invasive procedures, yet the frequency, management, and outcomes of temporary interruptions (TIs) in community practice are unknown. Methods: We assessed the frequency and reasons for TI in outpatients with AF enrolled in the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). Patient characteristics and use of bridging anticoagulants were analyzed. Endpoints included periprocedural adverse events (bleeding, thrombotic, or other) and cause-specific hospitalization within 30 days after TI. Results: Overall 7,372 patients were treated with OAC at baseline; 30% (n=2200) required at least 1 TI during median follow-up of 1 year. Patients requiring TI were similar in age (mean age 74 for both) and CHADS2 scores (mean 2.4 for both) to those not requiring TI. Among 3104 interruptions, the most commonly-identified reasons were for non-cardiac surgery (n=827, 27%), followed by endoscopic procedures (n=551, 18%) and cardiac catheterization (n=308, 10%). Bridging anticoagulants were used in 23% (n=709) of interruptions, including low-molecular weight heparin (n=512) or unfractionated heparin (n=109). Rates of bridging were highest during cardiac surgery (44%), cardiac catheterization (32%), and catheter ablation (33%). Patients with a prior stroke or TIA were significantly more likely to receive bridging (35% vs. 25%, p=0.0003), however there was no difference between patients with CHADS2 score >=2 vs. 0-1 (27% vs. 25%, p=NS). Adverse events during interruption were more common in bridged patients (5.1% vs. 2.9%, p=0.02), including bleeding events (3.6% vs. 1.8%, p=0.02); thrombotic events were uncommon (0.7 [n=4] vs. 0.5% [n=10], p=NS). After interruption, adverse events occurred early in follow-up (Figure), and bridged patients were more likely to experience any adverse event (13% vs. 6.3%, p<0.0001), cardiovascular hospitalization (4.3% vs. 2.3%, p=0.02), and bleeding hospitalization (2.2% vs. 0.7%, p=0.002) within 30 days. Conclusions: Temporary interruptions are common in patients receiving OAC for AF, however, bridging anticoagulation is used in a minority. Bleeding events following TI occurred significantly more often in patients receiving bridging anticoagulation.
Abstract 303: Adoption of the Novel Oral Anticoagulant Dabigatran in Patients with Atrial Fibrillation Receiving Warfarin in Community Practice: Findings from ORBIT AF
Piccini, Jonathan P. , Ansell, Jack , Chang, Paul, Kowey, Peter R. , Thomas, Laine , Holmes, DaJuanicia N. , Steinberg, Benjamin A. , Fonarow, Gregg C. , Gersh, Bernard J. , Mahaffey, Kenneth W. , Peterson, Eric D. , Hylek, Elaine M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 6 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.6.suppl_1.a303 Get It

Background: Dabigatran is a novel oral anticoagulant approved in October 2010 for thromboprophylaxis in atrial fibrillation (AF), yet patterns of adoption of this novel agent in clinical practice are unknown. Methods: Using the ORBIT-AF Registry, a national outpatient prospective AF registry involving 170 sites, we examined patterns of those switching to dabigatran from warfarin from 2010 to 2012. Results: Of 7,066 patients with AF receiving warfarin at baseline, 511 (7%) were switched to dabigatran during follow-up. Patients switched to dabigatran were younger (median age 73 vs. 76, p<0.0001), more likely to be White (94% vs. 89%, p=0.001), and had better kidney function (median creatinine clearance (CrCl) 77 mL/min vs. 69 mL/min, p<0.0001), but less likely to have a history of anemia, (14% vs. 18%, p=0.009) or history of any cerebrovascular disease (14% vs. 17%, p=0.04) or CAD (22% vs. 34%, p<0.0001) or be followed in an anticoagulation clinic (36% vs. 45%, p<0.0001). Patients switched to dabigatran were more likely to have been recently diagnosed with AF (5.3% vs. 3.0%, p=0.03), and their CHADS 2 scores were significantly lower (p<0.0001). Conclusions: Patients receiving warfarin who were switched to dabigatran were younger, with lower CHADS 2 scores, better kidney function, and less concomitant cardiovascular disease than those not switched. This conservative transition pattern suggests greater physician emphasis on bleeding avoidance than on stroke risk reduction.
Abstract 10: Contraindications to Oral Anticoagulation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
O’Brien, Emily C. , Koller, Christopher , Singer, Daniel E. , Ansell, Jack , Kowey, Peter R. , Chang, Paul, Ezekowitz, Michael D. , Piccini, Jonathan P. , Holmes, DaJuanicia N. , Allen, Larry A. , Hylek, Elaine M. , Gersh, Bernard J. , Fonarow, Gregg C. , Mahaffey, Kenneth W. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 6 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.6.suppl_1.a10 Get It

Background. Oral anticoagulation therapy (OAC) reduces the risk of thromboembolic events associated with atrial fibrillation (AF), yet a substantial proportion of patients with AF are not prescribed OAC. The frequencies of and factors associated with contraindications to OAC therapy in clinical practice are not well-described. Methods. We used data from the ORBIT-AF study, a national, prospective, outpatient registry of incident and prevalent AF. OAC contraindications were uniformly collected at study enrollment by site personnel. Patient and provider characteristics were compared between participants with documented OAC contraindications at baseline and those without OAC contraindications. Results. From June 2010 to August 2011, 10124 patients ≥18 years old with electrocardiographically documented AF were enrolled at 176 practices. Of these, 1409 (13.9%) had OAC contraindications documented at the baseline visit: prior bleed (26.2%), patient refusal/preference (26.0%), high bleeding risk (22.6%), frequent falls/frailty (16.6%), other (11.9%), need for dual antiplatelet therapy (9.8%), unable to adhere/monitor warfarin (5.7%), comorbid illness (5.0%), prior intracranial hemorrhage (4.7%), allergy (2.3%), occupational risk (0.8%), and pregnancy (0.2%). Compared to patients without contraindications, those with contraindications had higher stroke risk (CHADS2>2) and were older, more likely to be female, more likely to be seen by a cardiologist and less likely to be seen by an electrophysiologist (Table 1). Among those patients with reported contraindications, 28.4% were taking warfarin. Conclusions. Contraindications to OAC therapy among AF patients are common and often due to high bleeding risk. Furthermore, many patients with reported contraindications are taking warfarin, suggesting that many contraindications to warfarin therapy are minor, relative, or temporary.